CURE’s lymphoma cancer page is a go-to resource for oncology news and updates in the world of lymphoma cancer Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in lymphoma cancer.
October 21st 2024
Whenever I get sick, I experience a few side effects that usually go away, but unexplained weight loss becomes a problem for me.
September 23rd 2024
FDA Grants Priority Review to Revlimid Plus Rituxan for Indolent Non-Hodgkin Lymphoma
February 27th 2019The Food and Drug Administration granted a priority review to Revlimid (lenalidomide) plus Rituxan (rituximab) for the treatment of patients with previously treated follicular lymphoma and marginal zone lymphoma.
FDA Grants Priority Review to Antibody Drug Conjugate for Diffuse Large B-Cell Lymphoma
February 19th 2019The Food and Drug Administration granted a priority review to polatuzumab vedotin in combination with bendamustine plus Rituxan (rituximab) for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
My Candle in the Wind: Remembering a Loss to Hodgkin's Lymphoma
December 5th 2018Especially during holiday seasons, we remember loved ones who are not with us. Even long after they have passed, we can cherish old memories and even make new ones with the help of social media. Recently I learned something sweet about my brother John, who died of Hodgkin's lymphoma decades ago, from a high school friend I never knew about.
FDA Grants Adcetris a Breakthrough Therapy Designation for Rare Lymphoma
November 15th 2018The Food and Drug Administration (FDA) granted a breakthrough therapy designation to Adcetris (brentuximab vedotin) for the frontline treatment of certain lymphoma subtypes, according to Seattle Genetics, the manufacturer of the antibody-drug conjugate.
FDA Grants Fast Track Designation to Selinexor to Treat Diffuse Large B-cell Lymphoma
November 7th 2018The Food and Drug Administration (FDA) granted fast track designation to selinexor for the treatment of patients with diffuse large B-cell lymphoma (DLBCL), according to Karyopharm Therapeutics, the drug’s manufacturer.